En español
NIDA

NIDA Notes Advanced Search

Specific Drugs

Drug Topics

Related Topics

Do you like these search results?

See all RSS Feeds

Your search for Medication Development returned 36 results. Search again.

Treatment

Microneedle Milestone: One Week of Transdermal Drug Delivery

Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.

Basic Science

Stress-Induced Enzyme Compounds Methamphetamine Neurotoxicity

Ketoprofen, an anti-inflammatory agent commonly prescribed to treat arthritis, reduces neuronal damage in rats that have been exposed to chronic stress and methamphetamine. If this finding of a recent NIDA-supported study extrapolates to humans, anti-inflammatory medications may gain a place in the treatment of methamphetamine addiction.

Treatment

Naltrexone Implant Outperforms Daily Pill in Russian Trial

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

Treatment

Oxycodone Vaccine Passes Early Tests

A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.

Treatment

Gabapentin Tested To Treat Marijuana Dependence

Marijuana-dependent outpatients who were treated with the medication gabapentin in a pilot clinical trial reduced their cannabis use more and reported fewer symptoms of drug withdrawal than patients who received a placebo.

Treatment

N-Acetylcysteine Postsynaptic Effect Limits Efficacy

Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.

Treatment

Animation: Building an Anti-Drug Vaccine

The immune system has an extraordinary ability to recognize compounds foreign to the body and eliminate them. NIDA-sponsored scientists are working to harness this ability to create vaccines that will protect individuals against the psychogenic and addictive effects of abused drugs. This animation shows one of the most promising strategies, which has already yielded partial success in producing effective vaccines against nicotine, cocaine, and other drugs.

NIDA @ Work

Q&A: Dr. David Thomas

NIDA Program Officer Dr. David Thomas speaks about the intertwined problems of pain and prescription opioid abuse, as well as the research supported by NIDA and the National Institutes of Health to address these problems.

Treatment

Animal Research Advances Effort to Develop Vaccines Against Cocaine, Heroin Abuse

New vaccines that aim to promote recovery from cocaine and heroin abuse showed promise in animal testing. Both vaccines induced rats’ immune system to produce high titers of antibodies that inhibit the target drug from reaching the brain. The rats’ behaviors when given access to the target drug indicated that the vaccines reduced the reinforcing effects that, in recovering people, can cause lapses to turn into relapses.

Treatment

Potential Pain Medication Targets Peripheral Nerves

Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.

Treatment

More Convenient Preparations of Buprenorphine Pass Test

Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.

Treatment

Buprenorphine During Pregnancy Reduces Neonate Distress

Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.

Basic Science

Well-Known Mechanism Underlies Benzodiazepines' Addictive Properties

New research establishes that benzodiazepines cause addiction in a way similar to that of opioids, cannabinoids, and the club drug GHB. The discovery opens the door to designing new benzodiazepines that counteract anxiety but are not addictive.
Basic Science

In Animals, Receptor Puts Brakes on Nicotine Consumption

New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.

Bulletin Board

NIDA Announces Avant-Garde Medication Development Awards

Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
Basic Science

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

Reports on several studies implicating a certain neuropeptide (a signaling molecule) in fostering addition and overeating and discusses implications for addiction treatment.

Treatment

Medication Reduces Rats' Return to Methamphetamine Seeking

Reports on a new medication strategy under investigated in animal studies that shows promise for preventing relapse to drug abuse.

Bulletin Board

Three Scientists Join Advisory Council

Announces three new NIDA National Advisory Council on Drug Abuse members and describes their drug abuse and addiction research experience.
Bulletin Board

NIDA Appoints New Director of the Intramural Research Program

Announces NIDA’s new director of its intramural research program, Antonello Bonci, M.D., a leading researcher in neuropsychopharmacology.
Treatment

Modafinil Normalizes Sleep During Early Cocaine Abstinence

Describes a study investigating the effectiveness of modafinil in enhancing sleep among cocaine abusers who are currently abstinent.
Treatment

Cocaine Vaccine Helps Some Reduce Drug Abuse

Reports on the results of a clinical trial that tested the effectiveness of a cocaine vaccine designed as a therapy for cocaine abuse and plans underway for a new study of 300 patients to confirm these results.

Director's Perspective

New Tools and Strategies to Bolster Behavioral Therapy

Reports on research investigating whether certain medications might strengthen patients' understanding and memory retention.

Treatment

Medications That Normalize Brain Glutamate Reduce Drug-Seeking in Rats

Reports on two studies that demonstrate the promise of treating addiction with medications that alleviate drug-induced alterations in signaling by the neurotransmitter glutamate.
Bulletin Board

Dr. Phil Skolnick Now Leads NIDA's Medications Development Efforts

Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.
Treatment

Test Substance Attenuates Signs of Cocaine Withdrawal in Rats

Reports on several drugs that may ward off depression and anxiety, common withdrawal symptoms from cocaine, based on an animal study.

Treatment

Naltrexone via Skin Patch Proves Effectiveness of New Technology

Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.

Treatment

Combined Treatments Improve Dual Abstinence

Reports on a study investigating the effectiveness of a combined therapy of disulfiram and naltrexone for people who abuse cocaine and alcohol.

Treatment

Aripiprazole Prevents Rats From Resuming Cocaine Seeking

Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.

Director's Perspective

New Vaccines Are Being Developed Against Addiction and Relapse

Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.

Treatment

Selenium Shows Promise as an Adjunct Therapy for HIV

Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.

Treatment

Lofexidine May Enhance Naltrexone Efficacy

Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.

Treatment

Basic Science Discoveries Yield Novel Approaches to Analgesia

Describes research to develop new compounds that match or exceed the pain relief provided by opioids while avoiding their shortcomings.

Treatment

Endorphin Derivative Inhibits Reward From Morphine and Nicotine in Rats

Describes research investigating a naturally occurring brain chemical that shows early promise as a treatment for addiction in animal studies.

Vaccine May Reduce Fetal Exposure to Nicotine

Describes research on a vaccine developed to facilitate smoking cessation by blocking nicotine penetration into the brain.

Naltrexone-Nicotine Patch Combination Shows Promise

Reports findings from a clinical trial investigating the effectiveness of naltrexone as a supplement to nicotine replacement therapy for smoking cessation.
NIDA @ Work

How Drug Abuse Affects the Brain and Alters Behavior Are Key Questions Driving Division's Work

Discusses the work of NIDA’s Division of Basic Neuroscience and Behavioral Research, the Institute’s locus for studies into the fundamental brain mechanisms underlying drug abuse and addiction.
NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics